Cargando…

p27, The Cell Cycle and Alzheimer´s Disease

The cell cycle consists of successive events that lead to the generation of new cells. The cell cycle is regulated by different cyclins, cyclin-dependent kinases (CDKs) and their inhibitors, such as p27(Kip1). At the nuclear level, p27(Kip1) has the ability to control the evolution of different phas...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Osta, Ana, Dong, Jinya, Moreno-Aliaga, María Jesús, Ramirez, Maria Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835212/
https://www.ncbi.nlm.nih.gov/pubmed/35163135
http://dx.doi.org/10.3390/ijms23031211
_version_ 1784649373858136064
author García-Osta, Ana
Dong, Jinya
Moreno-Aliaga, María Jesús
Ramirez, Maria Javier
author_facet García-Osta, Ana
Dong, Jinya
Moreno-Aliaga, María Jesús
Ramirez, Maria Javier
author_sort García-Osta, Ana
collection PubMed
description The cell cycle consists of successive events that lead to the generation of new cells. The cell cycle is regulated by different cyclins, cyclin-dependent kinases (CDKs) and their inhibitors, such as p27(Kip1). At the nuclear level, p27(Kip1) has the ability to control the evolution of different phases of the cell cycle and oppose cell cycle progression by binding to CDKs. In the cytoplasm, diverse functions have been described for p27(Kip1), including microtubule remodeling, axonal transport and phagocytosis. In Alzheimer’s disease (AD), alterations to cycle events and a purported increase in neurogenesis have been described in the early disease process before significant pathological changes could be detected. However, most neurons cannot progress to complete their cell division and undergo apoptotic cell death. Increased levels of both the p27(Kip1) levels and phosphorylation status have been described in AD. Increased levels of Aβ42, tau hyperphosphorylation or even altered insulin signals could lead to alterations in p27(Kip1) post-transcriptional modifications, causing a disbalance between the levels and functions of p27(Kip1) in the cytoplasm and nucleus, thus inducing an aberrant cell cycle re-entry and alteration of extra cell cycle functions. Further studies are needed to completely understand the role of p27(Kip1) in AD and the therapeutic opportunities associated with the modulation of this target.
format Online
Article
Text
id pubmed-8835212
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88352122022-02-12 p27, The Cell Cycle and Alzheimer´s Disease García-Osta, Ana Dong, Jinya Moreno-Aliaga, María Jesús Ramirez, Maria Javier Int J Mol Sci Review The cell cycle consists of successive events that lead to the generation of new cells. The cell cycle is regulated by different cyclins, cyclin-dependent kinases (CDKs) and their inhibitors, such as p27(Kip1). At the nuclear level, p27(Kip1) has the ability to control the evolution of different phases of the cell cycle and oppose cell cycle progression by binding to CDKs. In the cytoplasm, diverse functions have been described for p27(Kip1), including microtubule remodeling, axonal transport and phagocytosis. In Alzheimer’s disease (AD), alterations to cycle events and a purported increase in neurogenesis have been described in the early disease process before significant pathological changes could be detected. However, most neurons cannot progress to complete their cell division and undergo apoptotic cell death. Increased levels of both the p27(Kip1) levels and phosphorylation status have been described in AD. Increased levels of Aβ42, tau hyperphosphorylation or even altered insulin signals could lead to alterations in p27(Kip1) post-transcriptional modifications, causing a disbalance between the levels and functions of p27(Kip1) in the cytoplasm and nucleus, thus inducing an aberrant cell cycle re-entry and alteration of extra cell cycle functions. Further studies are needed to completely understand the role of p27(Kip1) in AD and the therapeutic opportunities associated with the modulation of this target. MDPI 2022-01-21 /pmc/articles/PMC8835212/ /pubmed/35163135 http://dx.doi.org/10.3390/ijms23031211 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
García-Osta, Ana
Dong, Jinya
Moreno-Aliaga, María Jesús
Ramirez, Maria Javier
p27, The Cell Cycle and Alzheimer´s Disease
title p27, The Cell Cycle and Alzheimer´s Disease
title_full p27, The Cell Cycle and Alzheimer´s Disease
title_fullStr p27, The Cell Cycle and Alzheimer´s Disease
title_full_unstemmed p27, The Cell Cycle and Alzheimer´s Disease
title_short p27, The Cell Cycle and Alzheimer´s Disease
title_sort p27, the cell cycle and alzheimer´s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835212/
https://www.ncbi.nlm.nih.gov/pubmed/35163135
http://dx.doi.org/10.3390/ijms23031211
work_keys_str_mv AT garciaostaana p27thecellcycleandalzheimersdisease
AT dongjinya p27thecellcycleandalzheimersdisease
AT morenoaliagamariajesus p27thecellcycleandalzheimersdisease
AT ramirezmariajavier p27thecellcycleandalzheimersdisease